Drugs in Context is indexed in Clarivate JCR with a 2025 JIF of 2.8, is included in Clarivate ESCI, is a member of the Directory of Open Access Journals, and is listed on PubMed with all articles free-to-view/download immediately on PubMed Central
Drugs in Context publishes high-quality, peer-reviewed articles covering the latest evidence and innovations in pharmacotherapy and drug treatment across all therapeutic areas. We focus on original research papers and topical review articles; other article types are considered.
Clarivate JCR 2024 JIF: 2.8; JCI: 0.45; Category Ranking: 157/352, Q2
Scopus CiteScore 2024: 5.0; SCImago Journal Rank 2024: 0.775; Source Normalized Impact per Paper: 0.962; Ranked 94 of 668 (86th percentile) in General Medicine journals and 140 of 321 (56th percentile) in Pharmacology journals
We publish original research papers and topical review articles. Other article types, including systematic reviews and meta-analyses, editorials, case reports, conference reports and Letters to the Editor, are also considered
All manuscripts undergo single-blind external peer review with comments from at least two reviewers. A first editorial decision is aimed for within 4 weeks of submission and online publication within 4 weeks after acceptance
Check the SUBMISSION page for full instructions. Submit your manuscript via Manuscript Manager.
Drugs in Context is led by a team of Senior Editors supported by an extensive Editorial Board with expertise spanning all areas of modern medicine and pharmacotherapy.
Drugs in Context is an Open Access journal, with articles freely accessible online for all readers. Articles are assessed for suitability upon submission or pre-submission and then sent for external peer review. There is no charge for submitting a manuscript for consideration.
Publication in Drugs in Context is facilitated by our dedicated and responsive Editorial team. We offer simple and straightforward publication following best practices. For detailed submission guidelines, how to prepare your manuscript, timelines and charges, please read this section.
Lenacapavir (LEN), a first in-class capsid inhibitor, is approved as a twice-yearly subcutaneous injection for HIV prevention and represents a major advance beyond daily oral and bi-monthly injectable long-acting pre-exposure prophylaxis regimens.